Ratings Protalix BioTherapeutics, Inc.

Equities

PLX

US74365A3095

Real-time Estimate Cboe BZX Other stock markets 03:40:37 2024-05-28 pm EDT			5-day change	1st Jan Change
1.185 ^USD	-3.66%		-0.42%	-32.87%

May. 10	Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024
May. 10	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The group's activity appears highly profitable thanks to its outperforming net margins.
Its low valuation, with P/E ratio at 10.25 and 1.95 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PROTALIX BIOTHERAPEUTICS, INC.	-32.58%	90.18M	-
MODERNA, INC.	+54.44%	63.85B	B-
IQVIA HOLDINGS INC.	-1.38%	41.83B	B
LONZA GROUP AG	+40.34%	40.47B	A
CELLTRION, INC.	-10.02%	27.17B	C
ICON PUBLIC LIMITED COMPANY	+14.33%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.48%	18.69B	B
BIO-TECHNE CORPORATION	+3.37%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+22.20%	12.11B	B+
MEDPACE HOLDINGS, INC.	+28.52%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes